Individuals with type 1 diabetes (T1D) have demonstrated improvements in glycaemic control after transitioning away from daily insulin injections to Insult’s Omnipod 5 automated insulin delivery device.
The open label, single-arm Radiant study (NCT04196140) followed participants for a period of three-months in which they began by continuing their typical routine of multiple daily injections with a continuous glucose monitor (CGM) before transitioning onto Insulet’s Omnipod 5 device.
Go deeper with GlobalData
Results from the study showed that participants started with an average HbA1c level of 8.1%, which dropped to 0.8% after three months. Additionally, some participants with an HbA1c level higher than 8% at the start of the trial saw an improvement of 1% compared with injections and CGM.
Whilst seemingly a small figure, research published in the New England Journal of Medicine highlights how small decreases in HbA1c can still reduce the overall risk of developing later diabetes-related conditions such as cardiovascular disease or kidney disease.
Results from the randomised controlled trial were presented at the 2025 Advanced Technologies & Treatments for Diabetes (ATTD) congress, taking place in Amsterdam from 19 to 22 March.
“The RADIANT population was a cohort of individuals who, despite multiple daily injections and CGM, were not achieving target HbA1c levels. These participants, many of whom were waiting for a tubeless AID option, were able to safely transition directly from MDI to Omnipod 5 and achieve significant improvements in glucose levels,” said Dr Emma G Wilmot, associate professor at the University of Nottingham, Honorary Consultant Diabetologist in Derby and founder of the Diabetes Technology Network UK.
The trial specifically sought to recruit participants with HbA1c levels between 7.5% and 11% who were not previously meeting clinical targets, actively recruiting 188 participants at 19 sites across France the UK or Belgium.
Omnipod 5 is designed to be used in tandem with either Dexcom’s line of CGM devices or Abbott’s FreeStyle Libre 2 Plus.
Research by GlobalData’s Medical Device Database estimates that the insulin pump market brought in more than $7bn in 2024 alone, with that figure predicted to grow to $11bn by the end of the decade.
GlobalData is the parent company of Clinical Trials Arena.
Elsewhere in the field of diabetes treatment, the US Food and Drug Administration (FDA) has removed the clinical hold on vTv Therapeutics’ cadisegliatin clinical programme. Meanwhile, Vivani Medical has implanted the first patient with its weight loss device.
